Cargando…
Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
A novel therapy for improving selectivity in cancer chemotherapy aims to modify distribution of a cytotoxic drug by generating it selectively at tumour sites. In this approach an antibody-enzyme conjugate is allowed to localise at the tumour sites before injecting a prodrug which is converted to an...
Autores principales: | Antoniw, P., Springer, C. J., Bagshawe, K. D., Searle, F., Melton, R. G., Rogers, G. T., Burke, P. J., Sherwood, R. F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971568/ https://www.ncbi.nlm.nih.gov/pubmed/2257218 |
Ejemplares similares
-
A cytotoxic agent can be generated selectively at cancer sites.
por: Bagshawe, K. D., et al.
Publicado: (1988) -
Plasma and tissue disposition of mitozolomide in mice.
por: Brindley, C. J., et al.
Publicado: (1986) -
The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.
por: Melton, R. G., et al.
Publicado: (1990) -
Dichlorophosphinic bis(2-chloroethyl)amide
por: Song, Erqun, et al.
Publicado: (2012) -
tert-Butyl N-[N,N-bis(2-chloroethyl)sulfamoyl]-N-(2-chloroethyl)carbamate
por: Seridi, Achour, et al.
Publicado: (2009)